VistaGen presented at TD Cowen Health Care Conference on March 2, 2026
CEO highlighted pherine technology platform and lead asset fasedienol
Focus on neuropsychiatry and women's health treatments
Discussion acknowledged regulatory challenges in drug development
📖 Full Retelling
VistaGen Therapeutics (NASDAQ:VTGN) presented at the TD Cowen 46th Annual Health Care Conference on Monday, 02 March 2026, where CEO Shawn Singh highlighted the company's innovative pherine technology platform, lead asset fasedienol, and the potential of its drug candidates to revolutionize treatment in neuropsychiatry and women's health, reflecting both progress and challenges in navigating regulatory pathways. The presentation offered investors and industry stakeholders a comprehensive overview of VistaGen's proprietary pherine technology, which targets specific neural pathways to develop novel therapeutics for conditions with significant unmet medical needs. Singh emphasized the strategic importance of fasedienol, the company's lead compound, which has shown promising results in clinical trials for treating conditions such as major depressive disorder and premenstrual dysphoric disorder. The discussion also touched on VistaGen's broader pipeline and the company's approach to addressing complex regulatory requirements while advancing its innovative drug candidates toward commercialization.
Branch of medicine that treats mental disorders caused by diseases of the nervous system
Neuropsychiatry is a branch of medicine that deals with psychiatry as it relates to neurology, in an effort to understand and attribute behavior to the interaction of neurobiology and social psychological factors. Within neuropsychiatry, the mind is considered "as an emergent property of the brain",...
Fasedienol (INNTooltip International Nonproprietary Name; developmental code names PH94B and Aloradine), also known as 4-androstadienol or as 4,16-androstadien-3β-ol, is a pherine which is under development by VistaGen Therapeutics in a nasal spray formulation used as needed(PRN) for the acute treat...
On Monday, 02 March 2026, VistaGen Therapeutics (NASDAQ:VTGN) presented at the TD Cowen 46th Annual Health Care Conference, offering insights into its innovative pherine technology platform. CEO Shawn Singh highlighted the company’s progress and challenges, focusing on its lead asset, fasedienol, and the potential of its drug candidates to revolutionize treatment in neuropsychiatry and women’s health. While the discussion was optimistic, it reflected the complexities of navigating regulatory pathways.
